Global Recombinant Human Coagulation VIIa 麻豆原创 Insights, Forecast to 2030

Publication ID:

PB508240588

Publication Date:

August 6, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
The global Recombinant Human Coagulation VIIa market is projected to grow from US$ 1179.9 million in 2024 to US$ 1467.3 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.
Report Covers:
This report presents an overview of global market for Recombinant Human Coagulation VIIa, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Recombinant Human Coagulation VIIa, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Recombinant Human Coagulation VIIa, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant Human Coagulation VIIa sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Recombinant Human Coagulation VIIa market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Recombinant Human Coagulation VIIa sales, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
AryoGen Pharmed
GENERIUM
Segment by Type
Prefilled Syringe
Vial
Segment by Application
Congenital Hemophilia
Acquired Hemophilia
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Recombinant Human Coagulation VIIa in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Recombinant Human Coagulation VIIa manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Human Coagulation VIIa sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Study Coverage
1.1 Recombinant Human Coagulation VIIa Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Recombinant Human Coagulation VIIa 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Prefilled Syringe
1.2.3 Vial
1.3 麻豆原创 by Application
1.3.1 Global Recombinant Human Coagulation VIIa 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Congenital Hemophilia
1.3.3 Acquired Hemophilia
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Recombinant Human Coagulation VIIa Sales Estimates and Forecasts 2019-2030
2.2 Global Recombinant Human Coagulation VIIa Revenue by Region
2.2.1 Global Recombinant Human Coagulation VIIa Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Recombinant Human Coagulation VIIa Revenue by Region (2019-2024)
2.2.3 Global Recombinant Human Coagulation VIIa Revenue by Region (2025-2030)
2.2.4 Global Recombinant Human Coagulation VIIa Revenue 麻豆原创 Share by Region (2019-2030)
2.3 Global Recombinant Human Coagulation VIIa Sales Estimates and Forecasts 2019-2030
2.4 Global Recombinant Human Coagulation VIIa Sales by Region
2.4.1 Global Recombinant Human Coagulation VIIa Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Recombinant Human Coagulation VIIa Sales by Region (2019-2024)
2.4.3 Global Recombinant Human Coagulation VIIa Sales by Region (2025-2030)
2.4.4 Global Recombinant Human Coagulation VIIa Sales 麻豆原创 Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Recombinant Human Coagulation VIIa Sales by Manufacturers
3.1.1 Global Recombinant Human Coagulation VIIa Sales by Manufacturers (2019-2024)
3.1.2 Global Recombinant Human Coagulation VIIa Sales 麻豆原创 Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Human Coagulation VIIa in 2023
3.2 Global Recombinant Human Coagulation VIIa Revenue by Manufacturers
3.2.1 Global Recombinant Human Coagulation VIIa Revenue by Manufacturers (2019-2024)
3.2.2 Global Recombinant Human Coagulation VIIa Revenue 麻豆原创 Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Human Coagulation VIIa Revenue in 2023
3.3 Global Key Players of Recombinant Human Coagulation VIIa, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Recombinant Human Coagulation VIIa Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers 麻豆原创 Concentration Ratio (CR5 and HHI)
3.5.2 Global Recombinant Human Coagulation VIIa 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Product Offered and Application
3.8 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 麻豆原创 Size by Type
4.1 Global Recombinant Human Coagulation VIIa Sales by Type
4.1.1 Global Recombinant Human Coagulation VIIa Historical Sales by Type (2019-2024)
4.1.2 Global Recombinant Human Coagulation VIIa Forecasted Sales by Type (2025-2030)
4.1.3 Global Recombinant Human Coagulation VIIa Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Recombinant Human Coagulation VIIa Revenue by Type
4.2.1 Global Recombinant Human Coagulation VIIa Historical Revenue by Type (2019-2024)
4.2.2 Global Recombinant Human Coagulation VIIa Forecasted Revenue by Type (2025-2030)
4.2.3 Global Recombinant Human Coagulation VIIa Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Recombinant Human Coagulation VIIa Price by Type
4.3.1 Global Recombinant Human Coagulation VIIa Price by Type (2019-2024)
4.3.2 Global Recombinant Human Coagulation VIIa Price Forecast by Type (2025-2030)
5 麻豆原创 Size by Application
5.1 Global Recombinant Human Coagulation VIIa Sales by Application
5.1.1 Global Recombinant Human Coagulation VIIa Historical Sales by Application (2019-2024)
5.1.2 Global Recombinant Human Coagulation VIIa Forecasted Sales by Application (2025-2030)
5.1.3 Global Recombinant Human Coagulation VIIa Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Recombinant Human Coagulation VIIa Revenue by Application
5.2.1 Global Recombinant Human Coagulation VIIa Historical Revenue by Application (2019-2024)
5.2.2 Global Recombinant Human Coagulation VIIa Forecasted Revenue by Application (2025-2030)
5.2.3 Global Recombinant Human Coagulation VIIa Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Recombinant Human Coagulation VIIa Price by Application
5.3.1 Global Recombinant Human Coagulation VIIa Price by Application (2019-2024)
5.3.2 Global Recombinant Human Coagulation VIIa Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Recombinant Human Coagulation VIIa 麻豆原创 Size by Type
6.1.1 US & Canada Recombinant Human Coagulation VIIa Sales by Type (2019-2030)
6.1.2 US & Canada Recombinant Human Coagulation VIIa Revenue by Type (2019-2030)
6.2 US & Canada Recombinant Human Coagulation VIIa 麻豆原创 Size by Application
6.2.1 US & Canada Recombinant Human Coagulation VIIa Sales by Application (2019-2030)
6.2.2 US & Canada Recombinant Human Coagulation VIIa Revenue by Application (2019-2030)
6.3 US & Canada Recombinant Human Coagulation VIIa 麻豆原创 Size by Country
6.3.1 US & Canada Recombinant Human Coagulation VIIa Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Recombinant Human Coagulation VIIa Sales by Country (2019-2030)
6.3.3 US & Canada Recombinant Human Coagulation VIIa Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Recombinant Human Coagulation VIIa 麻豆原创 Size by Type
7.1.1 Europe Recombinant Human Coagulation VIIa Sales by Type (2019-2030)
7.1.2 Europe Recombinant Human Coagulation VIIa Revenue by Type (2019-2030)
7.2 Europe Recombinant Human Coagulation VIIa 麻豆原创 Size by Application
7.2.1 Europe Recombinant Human Coagulation VIIa Sales by Application (2019-2030)
7.2.2 Europe Recombinant Human Coagulation VIIa Revenue by Application (2019-2030)
7.3 Europe Recombinant Human Coagulation VIIa 麻豆原创 Size by Country
7.3.1 Europe Recombinant Human Coagulation VIIa Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Recombinant Human Coagulation VIIa Sales by Country (2019-2030)
7.3.3 Europe Recombinant Human Coagulation VIIa Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Recombinant Human Coagulation VIIa 麻豆原创 Size
8.1.1 China Recombinant Human Coagulation VIIa Sales (2019-2030)
8.1.2 China Recombinant Human Coagulation VIIa Revenue (2019-2030)
8.2 China Recombinant Human Coagulation VIIa 麻豆原创 Size by Application
8.2.1 China Recombinant Human Coagulation VIIa Sales by Application (2019-2030)
8.2.2 China Recombinant Human Coagulation VIIa Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Recombinant Human Coagulation VIIa 麻豆原创 Size by Type
9.1.1 Asia Recombinant Human Coagulation VIIa Sales by Type (2019-2030)
9.1.2 Asia Recombinant Human Coagulation VIIa Revenue by Type (2019-2030)
9.2 Asia Recombinant Human Coagulation VIIa 麻豆原创 Size by Application
9.2.1 Asia Recombinant Human Coagulation VIIa Sales by Application (2019-2030)
9.2.2 Asia Recombinant Human Coagulation VIIa Revenue by Application (2019-2030)
9.3 Asia Recombinant Human Coagulation VIIa Sales by Region
9.3.1 Asia Recombinant Human Coagulation VIIa Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Recombinant Human Coagulation VIIa Revenue by Region (2019-2030)
9.3.3 Asia Recombinant Human Coagulation VIIa Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa 麻豆原创 Size by Type
10.1.1 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa 麻豆原创 Size by Application
10.2.1 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa Sales by Country
10.3.1 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Recombinant Human Coagulation VIIa Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Overview
11.1.3 Novo Nordisk Recombinant Human Coagulation VIIa Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Novo Nordisk Recombinant Human Coagulation VIIa Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novo Nordisk Recent Developments
11.2 LFB SA HEMA Biologics
11.2.1 LFB SA HEMA Biologics Company Information
11.2.2 LFB SA HEMA Biologics Overview
11.2.3 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 LFB SA HEMA Biologics Recent Developments
11.3 AryoGen Pharmed
11.3.1 AryoGen Pharmed Company Information
11.3.2 AryoGen Pharmed Overview
11.3.3 AryoGen Pharmed Recombinant Human Coagulation VIIa Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 AryoGen Pharmed Recombinant Human Coagulation VIIa Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 AryoGen Pharmed Recent Developments
11.4 GENERIUM
11.4.1 GENERIUM Company Information
11.4.2 GENERIUM Overview
11.4.3 GENERIUM Recombinant Human Coagulation VIIa Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 GENERIUM Recombinant Human Coagulation VIIa Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 GENERIUM Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Human Coagulation VIIa Industry Chain Analysis
12.2 Recombinant Human Coagulation VIIa Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Human Coagulation VIIa Production Mode & Process
12.4 Recombinant Human Coagulation VIIa Sales and 麻豆原创ing
12.4.1 Recombinant Human Coagulation VIIa Sales Channels
12.4.2 Recombinant Human Coagulation VIIa Distributors
12.5 Recombinant Human Coagulation VIIa Customers
13 麻豆原创 Dynamics
13.1 Recombinant Human Coagulation VIIa Industry Trends
13.2 Recombinant Human Coagulation VIIa 麻豆原创 Drivers
13.3 Recombinant Human Coagulation VIIa 麻豆原创 Challenges
13.4 Recombinant Human Coagulation VIIa 麻豆原创 Restraints
14 Key Findings in The Global Recombinant Human Coagulation VIIa Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

Companies Mentioned:

Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
GENERIUM

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.